Fenoldopam Mesylate: A Narrative Review of Its Use in Acute Kidney Injury

Author(s): Annalisa Noce *, Giulia Marrone , Valentina Rovella, Andrea Busca, Caterina Gola, Michele Ferrannini, Nicola Di Daniele *.

Journal Name: Current Pharmaceutical Biotechnology

Volume 20 , Issue 5 , 2019

Submit Manuscript
Submit Proposal


Background: Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated.

Methods: We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury (AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced nephropathy.

Results and Conclusion: Fenoldopam mesylate was found to be effective in reducing the onset of postoperative AKI, when used before the development of the kidney damage. Positive results were also obtained in the management of intensive care unit patients with AKI, although the clinical studies investigated were few and conducted on small samples. Conflicting results were achieved in contrastinduced nephropathy.

Keywords: Fenoldopam mesylate, post-operative acute kidney injury, contrast-induced nephropathy, Intensive care unit-acute kidney injury, DA-1 receptor, dopamine, chronic kidney disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [366 - 375]
Pages: 10
DOI: 10.2174/1389201020666190417124711
Price: $95

Article Metrics

PDF: 8